^
Association details:
| Biomarker: | NRAS mutation |
|---|---|
| Cancer: | Melanoma |
| Drug: | Mektovi (binimetinib) (MEK inhibitor) + Kisqali (ribociclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity.
Excerpt:
Combined LEE011 + binimetinib shows promising preliminary antitumor activity in pts with NRAS-mutant melanoma.
DOI:
10.1200/jco.2014.32.15_suppl.9009
Trial ID:
Source:
Title:
A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity.
Excerpt:
Six pts achieved partial response (43%; 1 confirmed, 5 unconfirmed) and 6 had stable disease (4 with tumor shrinkage > 20%). Several pts experienced early tumor shrinkage with major symptomatic improvement; 8 pts remain on treatment (duration 2-8 mo). Conclusions: Combined LEE011 + binimetinib shows promising preliminary antitumor activity in pts with NRAS-mutant melanoma.
DOI:
10.1200/jco.2014.32.15_suppl.9009
Trial ID:
